The Clinical Question

Crohn’s disease is notorious for its unpredictable cycle of remission and relapse. While many patients can achieve a period of clinical inactivity, maintaining that status is a persistent challenge in gastroenterology. Traditional maintenance therapies, such as mesalamine or corticosteroids, are not always effective or well-tolerated over the long term.

Fish oil has long been of interest due to its natural anti-inflammatory properties, specifically its ability to reduce the production of inflammatory mediators like leukotrienes and cytokines. However, historical use was hampered by significant practical hurdles: patients often found the large doses required difficult to swallow, and the associated side effects—ranging from an unpleasant fishy aftertaste to heartburn and diarrhea—frequently led to patients abandoning the treatment. This study sought to determine if a novel, enteric-coated fish-oil preparation could effectively maintain remission in high-risk Crohn’s patients while overcoming these traditional barriers to compliance.

The Approach (Simplified)

The researchers conducted a one-year, double-blind, placebo-controlled trial involving 78 patients with Crohn’s disease. These participants were not just any patients; they were specifically chosen because they were at a high risk of relapse. To qualify, they had to be in clinical remission but also show at least one laboratory sign of ongoing inflammation, such as an elevated erythrocyte sedimentation rate (ESR) or high levels of certain serum proteins.

The 78 patients were split into two equal groups of 39.

• The Fish-Oil Group: Received nine capsules daily, providing a total of 2.7 grams of $n-3$ fatty acids.
• The Placebo Group: Received nine identical-looking capsules containing a mixed-acid triglyceride (a type of fat that does not have the same anti-inflammatory properties).

A critical feature of this study was the enteric coating of the capsules. This coating was designed to resist stomach acid for at least 30 minutes, only breaking down once the capsules reached the small intestine. This design aimed to prevent the “fishy burps” and gastric upset that typically plague fish-oil supplements.

The researchers monitored the patients for one year, checking them every three months to see if their disease stayed inactive or if they suffered a relapse. Relapse was strictly defined using the Crohn’s Disease Activity Index, a composite score based on symptoms like stool frequency, abdominal pain, and general well-being.

Key Findings (The Data)

The results showed a significant difference in the stability of remission between the two groups by the end of the 12-month period.

Relapse Rates

• In the placebo group, the majority of patients struggled to stay well: 69% (27 out of 39 patients) suffered a clinical relapse.
• In the fish-oil group, the results were considerably better: only 28% (11 out of 39 patients) experienced a relapse.
• This represents a 41% absolute reduction in the risk of relapse for those taking the fish oil.

Sustained Remission

When looking at who was still in remission at the end of the full year, 59% of the fish-oil group remained healthy, compared to just 26% of the placebo group. Statistical modelling confirmed that the fish-oil treatment was the only factor that truly influenced the likelihood of staying in remission; other factors like age, smoking status, or whether the patient had previously undergone surgery did not appear to make a difference.

Biological Evidence

The study didn’t just rely on how patients felt; it also looked at their blood chemistry.

• Inflammation markers: Patients in the fish-oil group saw a significant decrease in markers of inflammation, such as their ESR, while these markers tended to increase in the placebo group as they approached relapse.
• Cellular changes: By analyzing the red blood cells of the patients, the researchers found that the omega-3 fatty acids from the oil were actually being incorporated into the patients’ cell membranes, effectively displacing the fats that typically fuel inflammation.

Tolerability

The enteric coating appeared to work for most. There were no reports of the usual “fishy” side effects. However, diarrhea remained an issue for some: four patients in the fish-oil group (10%) dropped out because of increased bowel movements, compared to only one in the placebo group.

Strengths & Limitations

The study’s primary strength lies in its pragmatic design and the use of the enteric-coated delivery system, which addressed the most common reason for treatment failure with fish oils—poor compliance. By choosing a high-risk population (those with laboratory evidence of inflammation despite being in clinical remission), the researchers were able to demonstrate a very clear and robust effect over 12 months.

However, there are limitations to consider. The sample size of 78 patients is relatively small for a clinical trial. While the results were statistically strong, larger studies are usually preferred to ensure the findings apply to the broader, more diverse population of Crohn’s sufferers. Additionally, the 10% dropout rate due to diarrhea in the fish-oil group suggests that while the coating helps with gastric issues, it may deliver the oil too far down the digestive tract for some patients, potentially irritating the colon.

Finally, it is worth noting that the placebo used—a mixed-acid triglyceride—is a form of fat. While it was chosen to be biologically neutral, the study compares fish oil to a “fat placebo” rather than comparing it directly to existing standard treatments like mesalamine.

The Bottom Line

This study provides compelling evidence that a specific, enteric-coated fish-oil preparation can significantly reduce the risk of relapse in patients with Crohn’s disease who are currently in remission but remain at high risk. By reducing the relapse rate from 69% to 28%, this preparation offers a potentially powerful, naturally derived tool for long-term disease management. For the clinician, it suggests that “not all fish oils are created equal”—the delivery method is just as important as the dose when it comes to both efficacy and patient